Lipid Profile During Azathioprine or Mycophenolate Mofetil Combinations With Cyclosporine and Steroids

Transplantation Proceedings

Volumn 39, Issue 1, 2007, Pages 135-137

  Akman, B ^a   Uyar, M ^a   Afsar, B ^a   Sezer, S ^a   Ozdemir, F N ^a   Haberal, M ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENAL CORTEX HORMONES; ADULT; AZATHIOPRINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; TRIGLYCERIDES;

EID: 33846562469     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.10.210     Document Type: Article

References (14)

1. Singh A., Tejani C., Benfield M., et al. Sequential analysis of the lipid profile of children post-renal transplantation. Pediatr Transplant 2 (1998) 216
2. Pannu H.S., Singh D., and Sandhu J.S. Lipid profile before and after renal transplantation: a longitudinal study. Ren Fail 25 (2003) 411
3. Schena A., Di Paolo S., Morrone L.F., et al. Are lipid-dependent indicators of cardiovascular risk affected by renal transplantation?. Clin Transplant 14 (2000) 139
4. Shaheen F.A., Souqiyyeh M.Z., Shiek I.A., et al. Hypercholesterolemia in renal transplantation. Ann Transplant 6 (2001) 9
5. Hilbrands L.B., Demacker P.N., Hoitsma A.J., et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 5 (1995) 2073
6. Greenstein S.M., Sun S., Calderon T.M., et al. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Surg Res 91 (2000) 123
7. Romero F., Rodriguez-Iturbe B., Pons H., et al. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 152 (2000) 127
8. Mucha K., Foroncewicz B., Paczek L., et al. 36-month follow-up of 75 renal allograft recipients treated with steroids, tacrolimus, and azathioprine or mycophenolate mofetil. Transplant Proc 35 (2003) 2176
9. Wilson P.W.F., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837
10. Hricik D.E., and Schulak D.A. Metabolic effects of steroid withdrawal in adult renal transplant recipients. Kidney Int 44 suppl 43 (1993) S26
11. Kuster G.M., Drexel H., Bleisch C.H., et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 57 (1994) 1479
12. Quaschning T., Mainka T., Nauck M., et al. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int 71 (1999) S235
13. Land W. Future challenges in immunosupression. Transplant Proc 30 (1998) 1580
14. Boots J.M., Christiaans M.H., and van Hooff J.P. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 64 (2004) 2047